Tazemetostat(EPZ-6438) , 99% , 1403254-99-8
CAS NO.：1403254-99-8
Empirical Formula: C34H44N4O4
Molecular Weight: 572.74
MDL number: MFCD24849415
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB454.40 | In Stock |
|
| 25mg | RMB1598.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >162°C (dec.) |
| Boiling point: | 750.8±60.0 °C(Predicted) |
| Density | 1.163±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to at least 25 mg/ml). |
| pka | 11.92±0.10(Predicted) |
| form | solid |
| color | Off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
Description and Uses
Tazemetostat (1403254-99-8) is a potent (Ki = 2.5nM wild type human PRC2-containing) and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2.1?Tazemetostat displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines?in vitro. This antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. It displayed potent antitumor activity in various cancer models including non-Hodgkins lymphoma2, pediatric glioma3, small-cell carcinoma of the ovary4, and synovial sarcomas5. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.6
EPZ 6438 is a potent and selective inhibitor of EZH2.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 |
